Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Eton Pharmaceuticals Q4 2023 GAAP EPS $(0.09) Misses $(0.04) Estimate, Sales $7.313M Miss $7.700M Estimate

Author: Benzinga Newsdesk | March 14, 2024 04:17pm
Eton Pharmaceuticals (NASDAQ:ETON) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.04) by 125 percent. The company reported quarterly sales of $7.313 million which missed the analyst consensus estimate of $7.700 million by 5.03 percent. This is a 13.94 percent decrease over sales of $8.498 million the same period last year.

Posted In: ETON


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist